Washington, D.C. – Last week, the XR Association (XRA) endorsed S.723/H.R.1458, the bicameral, bipartisan Access to Prescription Digital Therapeutics Act of 2023, which would extend Medicare coverage for prescription digital therapeutics. The Act is sponsored by Senators Jeanne Shaheen (D-NH) and Shelly Moore Capito (R-WV) and Representatives Kevin Hern (OK-01) and Mike Thompson (CA-04).
XR technology is a rapidly evolving field that has already shown promising results in healthcare. Immersive technologies have proven effective in behavioral medicine, supporting patients with post-traumatic stress, autism, attention deficit hyperactivity disorder, substance abuse, and depression. If enacted, this legislation could expand patient access to these cutting-edge treatments.
Specifically, the bill would allow Medicare and Medicaid to cover the costs of prescription digital therapeutics that have been cleared/approved by the Federal Drug Administration (FDA) and are authorized by a licensed clinician.
XR technology has the potential to significantly reduce healthcare costs by enabling remote care, reducing the need for hospitalization, and improving patient outcomes. This bill could help to ensure that patients have access to innovative and beneficial therapies and are not burdened with the costs of these treatments.